在炎症性肠病中新兴的微生物组导向疗法:超越饮食修改和FMT
Andrea Carolina Quiroga-Centeno1,2, Konstantina Atanasova3, Matthias Philip Ebert3,4,5
1Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany. caroline_aqc@hotmail.com.
Seminars in immunopathology
|November 25, 2025
概括
新兴的微生物组导向疗法为炎症性肠病 (IBD) 提供了个性化策略. 这些先进的方法,包括工程细菌,旨在精确地恢复肠道健康并减少炎症,以更好地管理IBD.
科学领域:
- 胃肠道学和微生物学
- 肠道微生物组研究研究
- 炎症性肠病治疗方法 治疗方法
背景情况:
- 炎症性肠病 (IBD) 管理是具有挑战性的,因为其复杂性质和肠道微生物组的作用.
- 在IBD患者的肠道失生症驱动异常免疫反应,需要新的治疗策略.
- 目前的微生物干预措施,如益生菌和便微生物群移植 (FMT) 显示出有限的疗效,突出了对精密医学的需求.
研究的目的:
- 对炎症性肠病 (IBD) 的新兴微生物组导向疗法进行审查.
- 评估下一代益生菌,工程细菌和其他IBD微生物点的潜力.
- 讨论开发基于微生物组的创新IBD治疗的进展和挑战.
主要方法:
- 关于IBD微生物组导向治疗的最新科学文献的叙述性综述.
- 对合理设计的细菌联盟和基因工程细菌进行批判性评估.
- 在IBD中探索古菌,原生体,菌体和真菌的作用和治疗潜力.
主要成果:
- 新兴疗法专注于个性化策略,超越广泛的方法.
- 理性设计的联盟和工程细菌提供量身定制的微生物功能或在现场提供抗炎药物.
- 尚未探索的微生物组组成部分,如古生物和细菌菌体,呈现出新的治疗点.
结论:
- 创新的微生物组导向疗法有望恢复肠道平衡并减轻IBD中的炎症.
- 关键的挑战包括确保生态稳定性,植入,安全性,以及通过监管途径.
- 个性化,精确的微生物干预措施代表了IBD管理的未来.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
452
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
452
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
620
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
620
Inflammatory Bowel Disease V: Surgical Management
429
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
429
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Drugs for Treatment of Ulcerative Colitis in IBD
435
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
435


